ヌーペプト
| 製品名 | ヌーペプト |
| 別名 | GVS-111; N-Phenylacetyl-L-prolylglycine ethyl ester |
| CAS番号 | 157115-85-0 |
| 分子式 | C₁₇H₂₂N₂O₄ |
| 分子量 | 334.37 g/mol |
| 外観 | 白色からオフホワイトの結晶性粉末 |
| 分析（HPLC） | ≥ 99.0% |
| 融点 | 95–98°C |
| 乾燥減量 | ≤ 0.5% |
| 焼失残渣 | ≤ 0.1% |
| 重金属 | 10 ppm以下 |
お困りですか？ 弊社チームまでお問い合わせください
Noopept (developmental code GVS-111) is a dipeptide nootropic compound developed in Russia in the 1990s as a novel cognitive enhancer with neuroprotective properties. Structurally, it is a cycloprolyl-glycine derivative that shares some pharmacological similarities with racetams (particularly piracetam), but with significantly higher potency—estimated to be approximately 1,000 times more potent than piracetam.
Key : Unlike most nootropics that require weeks to show effects, Noopept has demonstrated rapid onset in research models. It exhibits both cognitive-enhancing そして neuroprotective properties, including protection against oxidative stress, excitotoxicity, and ischemia-reperfusion injury. Noopept also increases brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) levels in the hippocampus.
Noopept exerts its effects through multiple pathways, distinguishing it from classic racetams:
| Pathway | 仕組み | Research Finding |
|---|---|---|
| BDNF/NGF upregulation | Increases brain-derived neurotrophic factor and nerve growth factor in hippocampus | Supports synaptic plasticity, neurogenesis |
| AMPA/kainate receptor modulation | Positive allosteric modulation (similar to racetams) | Enhances glutamatergic transmission |
| 神経保護 | Reduces oxidative stress, inhibits lipid peroxidation, protects against excitotoxicity | Preclinical models of ischemia, traumatic brain injury |
| Cholinergic system | May enhance acetylcholine release (indirect) | Memory and learning support |
| 抗炎症作用 | Reduces neuroinflammation (preclinical) | 神経保護 |
Noopept has been shown to protect against neurodegeneration in animal models of Alzheimer’s disease, Parkinson’s disease, and cerebral ischemia. It reduces amyloid-β toxicity and may have disease-modifying potential (preclinical only).
リブバイオ株式会社. is a GMP-certified supplier of high-purity Noopept (GVS-111) for research and development applications.
供給能力：
分析法（HPLC）： ≥99.0%
フォーム： Crystalline powder
月間処理能力： 20+ kg
大量注文： 1g – 10kg
リードタイム: 3～5営業日（在庫品）
ドキュメント： COA, MSDS, HNMR , HPLC chromatogram, stability data
品質保証：
HPLC purity with UV detection
Residual solvents tested (meets USP <467>)
Heavy metals tested (ICP-MS)
Structural confirmation (NMR upon request)
📧 お問い合わせ： info@lyvbio.com
| パラメータ | 仕様 | 試験方法 |
|---|---|---|
| 分析（HPLC） | ≥ 99.0% | HPLC-UV (210 nm) |
| 外観 | 白色からオフホワイトの結晶性粉末 | ビジュアル |
| 識別 | HPLC保持時間、NMR（ご要望に応じて） | HPLC / NMR |
| 融点 | 95–98°C | USP |
| 乾燥減量 | ≤ 0.5% | USP |
| 焼失残渣 | ≤ 0.1% | USP |
| 重金属 | Pb ≤ 10 ppm; As ≤ 2 ppm; Cd ≤ 1 ppm; Hg ≤ 0.1 ppm | ICP-MS |
| 関連物質 | 単一不純物 ≤ 0.5%；合計 ≤ 1.0% | HPLC-UV |
| 残留溶剤 | USP について | GC |
| 粒子径 | 95%～80メッシュ | ふるい分析 |
Q: Is Noopept the same as Piracetam?
A: No. Noopept is a dipeptide derivative with different chemical structure, significantly higher potency (~1,000x), and distinct mechanisms (including BDNF/NGF upregulation). It is not a racetam, though it shares some pharmacological similarities.
Q: Is Noopept FDA-approved?
A: No. Noopept is not FDA-approved for medical use in the United States. It is available as a research chemical for laboratory use only. It has been used as a prescription medication in Russia.
Q: What is the difference between Noopept and other nootropics?
A: Noopept is unique in its ability to upregulate BDNF and NGF in the hippocampus—a property not shared by classic racetams. It is also significantly more potent (microgram vs. milligram dosing).
Q: What is the primary active metabolite of Noopept?
A: Cycloprolylglycine (CPG). Noopept is rapidly metabolized to CPG, which is believed to contribute significantly to its pharmacological effects.
Q: Does Noopept have neuroprotective properties?
A: Yes. Preclinical studies have demonstrated neuroprotective effects in models of stroke, traumatic brain injury, excitotoxicity, and neurodegeneration (Alzheimer’s, Parkinson’s models).
Q: What is the effective dose range in animal studies?
A: Published studies report cognitive-enhancing and neuroprotective effects at 0.1–1 mg/kg (oral) in rodents—approximately 1,000 times more potent than piracetam.
Q: Are there human clinical trials for Noopept?
A: Limited human studies have been conducted in Russia, where Noopept is approved as a prescription nootropic.
お問い合わせ： info@lyvbio.com
English English 
Russian
French
Korean
German
Polish
Japanese
Spanish
Italian
Vietnamese